Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ahead of schedule. The ...

WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource focused on treatment considerations during ...

MYC targeted therapies offer significant market opportunities, driven by their potential as oncogenic drivers in diverse tumors. The field sees growing R&D on innovative platforms, early-stage ...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to ...

PLYMOUTH MEETING, Pa., March 29, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients ...

The future of clinical research depends on people just as much as strong systems and processes. Learn what makes great ...

The clinical trials landscape will continue evolving toward greater decentralization, enhance patient-centricity, and increased global diversification. Industry projections suggest that by 2025, ...

Logistics companies provide an essential service for clinical trials, but providers must be compliant with regulations. Learn ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical ...